From this perspective, if the role of c-Myc in immune evasion can be confirmed through future clinical experiments, then targeting the c-Myc/PD-L1 axis may serve as a potential therapeutic strategy for hematological disorders caused by benzene exposure. The gene discussed is CD274; the disease is hematologic disorder.